HighGravityDataSigned in · PRO
Guidance history, every release
Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing
| Metric | Oct 24, 2024 FY24 Q3 | Feb 6, 2025 FY24 Q4 | Apr 29, 2025 FY25 Q1 | Jul 24, 2025 FY25 Q2 | Oct 28, 2025 FY25 Q3 | Feb 17, 2026 FY25 Q4 | Apr 30, 2026 FY26 Q1 | Jul 30, 2026 FY26 Q2 |
|---|---|---|---|---|---|---|---|---|
| For FY2026 | ||||||||
| Biopharma Laboratory Services Revenue | — | — | — | — | — | — | New“$3.22 $3.27” | — |
| Diagnostics Laboratories Revenue | — | — | — | — | — | — | New“$11.43 $11.52” | — |
| Enterprise Revenue | — | — | — | — | — | — | New“5.0% to 6.1%” | — |
| Labcorp Enterprise Revenue | — | — | — | — | — | — | New“$14.65 $14.80” | — |
| Revenue | — | — | — | — | — | New“$14.61 billion to $14.79 billion” | — | — |
| Revenue - Labcorp Enterprise (dollar) | — | — | — | — | — | New“$14.61 billion to $14.79 billion” | — | — |
| Adjusted EPS | — | — | — | — | — | New“$17.55 to $18.25” | Raised“$17.70 to $18.35” | — |
| Adjusted EPS midpoint | — | — | — | — | — | — | New“$18.03” | — |
| Adjusted EPS range | — | — | — | — | — | — | — | New“$18.10 to $18.55” |
| Free Cash Flow | — | — | — | — | — | New“$1.24 billion to $1.36 billion” | Reiterated“$1.24 $1.36” | — |
| Quarterly cash dividend | — | — | — | — | — | New“$0.72 per share of common stock” | Reiterated“$0.72 per share” | — |
| Quarterly cash dividend per share | — | — | — | — | — | — | — | New“$0.72” |
| For FY2025 | ||||||||
| Revenue | — | New“$13.88 billion to $14.05 billion” | — | — | — | — | — | — |
| Revenue - Labcorp Enterprise (dollar) | — | New“$13.88 billion to $14.05 billion” | — | — | — | — | — | — |
| Adjusted EPS | — | New“$15.60 to $16.40” | — | — | — | — | — | — |
| Adjusted EPS (Updated 2025) | — | — | — | New“$16.05 to $16.50” | — | — | — | — |
| Adjusted EPS range | — | — | New“$15.70 to $16.40” | — | Raised“$16.15 to $16.50” | — | — | — |
| Free Cash Flow | — | New“$1.10 billion to $1.25 billion” | Reiterated“$1.10 billion to $1.25 billion” | Raised“$1.13 billion to $1.28 billion” | — | — | — | — |
| Free Cash Flow range | — | — | — | — | New“$1.17 billion to $1.29 billion” | — | — | — |
| Quarterly cash dividend | — | New“$0.72 per share of common stock” | — | Reiterated“$0.72 per share of common stock” | Reiterated“$0.72 per share of common stock” | — | — | — |
| Quarterly cash dividend | — | — | New“$0.72 per share of common stock” | — | — | — | — | — |
| For FY2024 | ||||||||
| Revenue - Labcorp Enterprise (growth range) | New“6.6% to 7.3%” | — | — | — | — | — | — | — |
| Adjusted EPS range | New“$14.30 to $14.70” | — | — | — | — | — | — | — |
| Free Cash Flow | New“$850 million to $980 million” | — | — | — | — | — | — | — |
| Quarterly cash dividend | New“$0.72 per share of common stock, payable on December 13, 2024, to stockholders of record at the close of business on November 26, 2024” | — | — | — | — | — | — | — |
| No period stated | ||||||||
| Next Twelve Months Forecast Backlog Conversion | — | — | New“$2.56” | — | Raised“$2.66” | — | — | Raised“$2.75” |
| Quarterly cash dividend | New“$0.72 per share” | Reiterated“$0.72 per share” | Reiterated“$0.72 per share” | Reiterated“$0.72 per share” | Reiterated“$0.72 per share” | Reiterated“$0.72 per share” | — | Reiterated“$0.72 per share” |
| Share repurchase authorization increase | — | — | — | — | — | — | — | New“$1.0 billion” |
| Share repurchase authorization, remaining total | — | — | — | — | — | — | — | New“$1.4 billion” |
Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.